SCHEMBL25548965

SCHEMBL25548965

C#CC(C)(C)C(NC(=O)c1ccc2ccccc2c1OCc1ccc(C(F)(F)F)cc1)C(=O)OCC

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CXCR2 P25025 3/20 0.57
▸ PPARG P37231 4/20 0.37
▸ EPHX2 P34913 2/20 0.37
▸ MAOB P27338 1/20 0.37
▸ P2RX1 P51575 1/20 0.36
▸ P2RX3 P56373 1/20 0.36
▸ P2RX4 Q99571 1/20 0.36
▸ P2RX7 Q99572 1/20 0.36
▸ DRD4 P21917 1/20 0.35
▸ TACR1 P25103 1/20 0.35
▸ MCHR1 Q99705 1/20 0.35
▸ LMNA P02545 2/20 0.35
▸ GAA P10253 2/20 0.35
▸ MAPT P10636 2/20 0.35
▸ MAPK1 P28482 2/20 0.35
▸ HTT P42858 2/20 0.35
▸ SMN1; SMN2 Q16637 2/20 0.35
▸ KDM4E B2RXH2 1/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ NPSR1 Q6W5P4 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23461051 0.91 CXCR2 (0.59) CXCR2PPARGP2RX1P2RX3P2RX4
SCHEMBL38147033 0.91 CXCR2 (0.59) CXCR2PPARGP2RX1P2RX3P2RX4
SCHEMBL25548967 0.90 CXCR2 (0.46) CXCR2PPARGEPHX2MAPT
SCHEMBL25549128 0.90 CXCR2 (0.45) CXCR2EPHX2LMNAGAAMAPT
SCHEMBL23460659 0.83 CXCR2 (0.67) CXCR2PPARGP2RX1P2RX3P2RX4
SCHEMBL23460658 0.83 CXCR2 (0.67) CXCR2PPARGP2RX1P2RX3P2RX4
SCHEMBL23461016 0.82 CXCR2 (0.47) CXCR2PPARGMAOBMMEACE
SCHEMBL38147032 0.82 CXCR2 (0.47) CXCR2PPARGMAOBMMEACE
SCHEMBL25548737 0.82 CXCR2 (0.64) CXCR2PPARGP2RX1P2RX3P2RX4
SCHEMBL25549891 0.82 CXCR2 (0.64) CXCR2PPARGP2RX1P2RX3P2RX4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230159438-A1 ARYLAMIDES AND METHODS OF USE THEREOF GENZYME CORPORATION 2023-05-25 — — US disclosed
US-20230159438-A1 ARYLAMIDES AND METHODS OF USE THEREOF GENZYME CORPORATION 2023-05-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159438-A1 ARYLAMIDES AND METHODS OF USE THEREOF CFTR, AADAC, ARSA CXCR2 1205/4885PPARG 731/4885EPHX2 1774/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback